SkylineDx and NeraCare team up to develop Immunoprint test

Source: Medical Device, April 2023

Dutch diagnostics corporation SkylineDx and German company NeraCare have entered a strategic partnership to advance precision medicine for early-stage melanoma.

The collaboration will work on the co-development of a test to help life science companies bring therapies for melanoma to market.

It includes an exclusive agreement for the co-development and licensing of NeraCare’s Immunoprint proteomic test which identifies early-stage melanoma patients who are at high risk of relapse and death.
READ THE ORIGINAL FULL ARTICLE